Literature DB >> 15601318

Expression of chromogranins A, B, and C (secretogranin II) in human adrenal medulla and in benign and malignant pheochromocytomas An immunohistochemical study with region-specific antibodies.

Guida Maria Portela-Gomes1, Mats Stridsberg, Lars Grimelius, Ursula G Falkmer, Sture Falkmer.   

Abstract

In a recent immunohistochemical study of pheochromocytomas, a difference was observed between benign and malignant pheochromocytomas in their expression in different parts of the chromogranin (Cg) A molecule. The purpose of the present study was to extend the investigations by including two other members of this Cg family, CgB and C. Twenty-five patients operated on for clinicopathologically benign pheochromocytomas, and four for metastasizing pheochromocytomas, were studied. Expression of the different Cg regions was studied immunohistochemically by means of region-specific antibodies: four raised against CgA epitopes, five against CgB, and two against CgC. Adrenal medulla parenchyma from three surgical adrenalectomy specimens was used as non-neoplastic control. All cells of normal adrenal medulla were immunoreactive to all 11 region-specific Cg antibodies. In the pheochromocytomas, variations in the expression pattern occurred, but no significant quantitative differences were noted between benign and malignant tumours. Nevertheless, in all four malignant pheochromocytomas, the antibodies raised against the C-terminal regions of both CgB and CgC visualised a noticeable population of large spindle-shaped tumour cells, characterised by elongated processes. This cell type occurred in all four malignant pheochromocytomas but only in one benign tumour. Their structure and immunoreactivity differed from those of the sustentacular cells in the pheochromocytoma parenchyma. The use of region-specific antibodies raised against epitopes in the C-terminal region of CgB and CgC can facilitate the diagnosis of malignant pheochromocytoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15601318     DOI: 10.1111/j.1600-0463.2004.t01-1-apm1121003.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  8 in total

Review 1.  Immunohistochemical and biochemical studies with region-specific antibodies to chromogranins A and B and secretogranins II and III in neuroendocrine tumors.

Authors:  Guida M Portela-Gomes; Lars Grimelius; Mats Stridsberg
Journal:  Cell Mol Neurobiol       Date:  2010-11-03       Impact factor: 5.046

Review 2.  Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.

Authors:  Oliver Gimm; Catherine DeMicco; Aurel Perren; Francesco Giammarile; Martin K Walz; Laurent Brunaud
Journal:  Langenbecks Arch Surg       Date:  2011-11-29       Impact factor: 3.445

3.  Differential Expression of Secretogranins II and III in Canine Adrenal Chromaffin Cells and Pheochromocytomas.

Authors:  Hiroshi Gomi; Takahiro Nagumo; Kazushi Asano; Makoto Konosu; Tadashi Yasui; Seiji Torii; Masahiro Hosaka
Journal:  J Histochem Cytochem       Date:  2022-04-09       Impact factor: 4.137

4.  Immunohistochemical staining of human islet cells with region-specific antibodies against secretogranins II and III.

Authors:  M Stridsberg; L Grimelius; G M Portela-Gomes
Journal:  J Anat       Date:  2008-01-25       Impact factor: 2.610

5.  Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors.

Authors:  Allison B Weisbrod; Lisa Zhang; Meenu Jain; Stephanie Barak; Martha M Quezado; Electron Kebebew
Journal:  Horm Cancer       Date:  2013-01-30       Impact factor: 3.869

Review 6.  Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas.

Authors:  Aoife J Lowery; Siun Walsh; Enda W McDermott; Ruth S Prichard
Journal:  Oncologist       Date:  2013-04-10

7.  Chromogranin A - unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls.

Authors:  Paweł Gut; Agata Czarnywojtek; Jakub Fischbach; Maciej Bączyk; Katarzyna Ziemnicka; Elżbieta Wrotkowska; Maria Gryczyńska; Marek Ruchała
Journal:  Arch Med Sci       Date:  2016-02-02       Impact factor: 3.318

8.  Identification of Clinical Relevant Molecular Subtypes of Pheochromocytoma.

Authors:  Umair Ali Khan Saddozai; Fengling Wang; Muhammad Usman Akbar; Lu Zhang; Yang An; Wan Zhu; Longxiang Xie; Yongqiang Li; Xinying Ji; Xiangqian Guo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-21       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.